Citius Pharmaceuticals, Inc. (CTXR) Earnings History
Annual and quarterly earnings data from 2011 to 2025
Loading earnings history...
CTXR EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CTXR Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export CTXR earnings history in CSV or JSON format
Free sign-in required to download data
Citius Pharmaceuticals, Inc. (CTXR) Earnings Overview
As of May 8, 2026, Citius Pharmaceuticals, Inc. (CTXR) reported trailing twelve-month net income of -$37M, reflecting +43.4% year-over-year growth. The company earned $-2.07 per diluted share over the past four quarters.
Looking at the long-term picture, CTXR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$22,006 in fiscal 2012.
Citius Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NKTR (-$164M net income, -297.1% margin), HALO ($317M net income, 22.7% margin), PRGO (-$1.82B net income, -33.5% margin), CTXR has comparable earnings metrics. Compare CTXR vs NKTR →
CTXR Earnings vs Peers
Earnings metrics vs comparable public companies
CTXR Historical Earnings Data (2011–2025)
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$37M | +4.4% | -$39M | $-3.38 | - | - |
| 2024 | -$39M | -20.3% | -$42M | $-5.97 | - | - |
| 2023 | -$33M | +3.3% | -$37M | $-5.57 | - | - |
| 2022 | -$34M | -45.5% | -$33M | $-5.76 | - | - |
| 2021 | -$23M | -31.8% | -$24M | $-5.64 | - | - |
| 2020 | -$18M | -12.6% | -$18M | $-0.45 | - | - |
| 2019 | -$16M | -24.3% | -$16M | $-0.77 | - | - |
| 2018 | -$13M | -20.7% | -$14M | $-1.17 | - | - |
| 2017 | -$10M | -25.2% | -$10M | $-1.89 | - | - |
| 2016 | -$8M | -185.8% | -$7M | $-2.29 | - | - |
See CTXR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTXR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CTXR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCTXR — Frequently Asked Questions
Quick answers to the most common questions about buying CTXR stock.
Is CTXR growing earnings?
CTXR EPS is $-2.07, with earnings growth accelerating to +43.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-37M.
What are CTXR's profit margins?
Citius Pharmaceuticals, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are CTXR's earnings?
CTXR earnings data spans 2011-2025. The accelerating earnings trend is +43.4% YoY. Historical data enables comparison across business cycles.